Mylan N.V. (MYL) reported its financial results for the quarter ended March 31, 2020, on Monday before the market opens. The company reaffirmed its financial guidance for the full-year 2020.
The results were driven by overall volume growth, which was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic, primarily in its Europe segment.
Looking ahead, Mylan remains on track to close the pending combination with Pfizer’s Upjohn Business in the second half of the year.
Take a look at the company's earnings in graphical format here
The results were driven by overall volume growth, which was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic, primarily in its Europe segment.
Looking ahead, Mylan remains on track to close the pending combination with Pfizer’s Upjohn Business in the second half of the year.
Take a look at the company's earnings in graphical format here